Market News
Global Bioelectric Medicine Market- Recent Developments
Product Launch & Approval
- On January 8, 2024, Tivic Health Systems, Inc., a commercial-phase health technology company that develops and commercializes bioelectronic medicine launched the second generation of Tivic ClearUP. ClearUP 2.0, a clinically proven way to clear congestion and relieve sinus pain. It is an U.S.FDA-approved, 100% drug-free and non-addictive way to reduce sinus pain, pressure, sinus headaches, and congestion due to colds, flu, and allergies.
- On January 8, 2024, Medtronic plc., one of the global leader in healthcare technology announced the U.S. Food and Drug Administration (FDA) approval of its percept rechargeable deep brain stimulation (DBS) system. Percept RC is the smallest and thinnest dual channel‡ neurostimulator available for DBS.
- In February 2021, Pulse Biosciences, Inc., a novel bioelectric medicine company progressing nano-pulse stimulationtechnology, announced that the first clinic patients have been treated with the CellFX System. The CellFX System is the first commercial product to harness the distinctive advantages of the company’s proprietary nano-pulse stimulation technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue.
Key Strategic Initiatives:
- In October 2024, GE HealthCare, one of the leading global medical technology company announced a collaboration with Novo Nordisk, one of the leading global healthcare company to further advance the clinical and product development of peripheral focused ultrasound (PFUS). PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease.
U.S.: 
U.K. : 
India : 
